Volume Alert - MRK 59.09 Merck & Company $MRK Hit a high today of 59.55 Closing the day 10:30 at 59.09 -0.45 -0.76% With a day low of 58.95 and a total volume of 1,027,203.
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Dow Jones (DJIA) Today: Cisco Systems (CSCO) Leads The Day Higher, Merck (MRK) Lags
at The Street - 2 hrs 52 mins ago
The Dow component leading the way higher looks to be Cisco Systems (Nasdaq:CSCO), which is sporting a 36-cent gain (+1.4%) bringing the stock to $26.04. Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a...
MRK: 58.97 (-0.57), CSCO: 26.18 (+0.50)
Merck (MRK) Breaks Through Support at $59.16
Comtex SmarTrend(R) - Fri Nov 14, 10:14AM CST
Merck (NYSE:MRK) has opened bearishly below the pivot of $59.56 today and has reached the first level of support at $59.16. Analysts will be watching for a cross of the next downside pivot targets of $58.79 and $58.02.
MRK: 58.97 (-0.57)
Merck Supports Free Diabetes Screening For More Than 19,000 Community Members in India and Africa on World Diabetes Day, as Part of Merck Diabetes Capacity Advancement Program (CAP)
M2 - Fri Nov 14, 6:21AM CST
African Press Organization (APO)/ - On the occasion of World Diabetes Day (WDD), Merck is conducting Diabetes awareness camps in India, Kenya and Ghana in collaboration with Maharashtra University and Government in India and with Kenya Ministry of health, Diabetes Management and Information center (DMI) and National Diabetes Association of Ghana.
MRK: 58.97 (-0.57)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.18 (-0.89), GILD: 101.52 (-2.68), MRK: 58.97 (-0.57), ABBV: 63.70 (+0.07)
Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:56AM CST
PFE: 30.25 (-0.17), MRK: 58.97 (-0.57), BMY: 57.68 (-0.12), NVS: 93.87 (-0.51)
Merck Joins Kenya Ministry Of Health Kenya Diabetes Management and Information Center (DMI) to Celebrate The World Diabetes Day
M2 - Thu Nov 13, 9:11AM CST
o Merck supports diabetes medical education and community awareness as part of its Capacity Advancement Program - CAP in Kenya.
MRK: 58.97 (-0.57)
Merck Aims to Support Free Diabetes Screening For More Than 15,000 Community Members in collaboration with Maharashtra University as Part of Its Capacity Advancement Program In India
M2 - Thu Nov 13, 9:11AM CST
o On the occasion of World Diabetes Day, Merck is conducting Diabetes awareness camps at 15 medical colleges in Maharashtra University.
MRK: 58.97 (-0.57)
BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - Thu Nov 13, 8:10AM CST
PFE: 30.25 (-0.17), MRK: 58.97 (-0.57), AZN: 72.73 (-1.80), BIND: 10.21 (+0.30)
Gene mutation targeted by Merck's Zetia leads to lower cholesterol levels and reduced heart disease risk
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:01AM CST
MRK: 58.97 (-0.57)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 58.97 (-0.57), INCY: 68.72 (-2.49), CLDX: 13.73 (-0.53), NLNK: 30.59 (-0.41), GSK: 45.70 (+0.04), BMY: 57.68 (-0.12), SRNE: 4.13 (-0.08)
Samsung Leads in Printed, Flexible and Organic Electronics Innovation
Marketwired - Thu Nov 13, 6:30AM CST
Samsung, Merck, BASF, Sony and Philips are the world's leading innovators in printed, flexible and organic electronics (PFOE), according to Lux Research, which rated corporations based on both internal R&D spending and open innovation activities. Samsung Electronics is the standout with estimated PFOE R&D spending of $1.2 billion, as well as high open innovation scores due to its extensive outside partnerships and investments.
MRK: 58.97 (-0.57)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 108.18 (-0.89), MRK: 58.97 (-0.57), AMGN: 156.93 (-3.92), LLY: 67.16 (-0.52), GSK: 45.70 (+0.04), BMY: 57.68 (-0.12)
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.69 (+0.20), MRK: 58.97 (-0.57), ABBV: 63.70 (+0.07)
Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
Shock Exchange - at Seeking Alpha - Wed Nov 12, 2:13PM CST
GILD: 101.53 (-2.67), MRK: 58.97 (-0.57)
Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - Wed Nov 12, 12:44PM CST
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote. The reason, he said, is...
JNJ: 108.18 (-0.89), PFE: 30.25 (-0.17), MRK: 58.97 (-0.57), AMGN: 156.95 (-3.90), MO: 48.65 (-0.80), CVX: 115.92 (-0.53)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.00 (-0.24), AGN: 197.90 (+1.69), HLF: 38.29 (+0.44), VRX: 134.35 (+2.45), PFE: 30.25 (-0.17), MRK: 58.97 (-0.57), LLY: 67.16 (-0.52)
This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 101.53 (-2.67), ACHN: 13.69 (+0.20), MRK: 58.97 (-0.57)
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 58.97 (-0.57), NVS: 93.87 (-0.51)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.52 (+0.01), JNJ: 108.18 (-0.89), IDRA: 2.40 (-0.05), DERM: 15.83 (-0.41), MRK: 58.97 (-0.57), PFE: 30.25 (-0.17), AZN: 72.73 (-1.80), AMGN: 156.95 (-3.90), GSK: 45.70 (+0.04), HSP: 57.98 (-0.11), NVS: 93.87 (-0.51), CELG: 103.04 (-4.39)
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 101.52 (-2.68), MRK: 58.97 (-0.57)
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
Dow Jones (DJIA) Today: Cisco Systems (CSCO) Leads The Day Higher, Merck (MRK) Lags
at The Street - 2 hrs 52 mins ago
The Dow component leading the way higher looks to be Cisco Systems (Nasdaq:CSCO), which is sporting a 36-cent gain (+1.4%) bringing the stock to $26.04. Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a...
MRK: 58.97 (-0.57), CSCO: 26.18 (+0.50)
Merck (MRK) Breaks Through Support at $59.16
Comtex SmarTrend(R) - Fri Nov 14, 10:14AM CST
Merck (NYSE:MRK) has opened bearishly below the pivot of $59.56 today and has reached the first level of support at $59.16. Analysts will be watching for a cross of the next downside pivot targets of $58.79 and $58.02.
MRK: 58.97 (-0.57)
Merck Supports Free Diabetes Screening For More Than 19,000 Community Members in India and Africa on World Diabetes Day, as Part of Merck Diabetes Capacity Advancement Program (CAP)
M2 - Fri Nov 14, 6:21AM CST
African Press Organization (APO)/ - On the occasion of World Diabetes Day (WDD), Merck is conducting Diabetes awareness camps in India, Kenya and Ghana in collaboration with Maharashtra University and Government in India and with Kenya Ministry of health, Diabetes Management and Information center (DMI) and National Diabetes Association of Ghana.
MRK: 58.97 (-0.57)
The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST
JNJ: 108.18 (-0.89), GILD: 101.52 (-2.68), MRK: 58.97 (-0.57), ABBV: 63.70 (+0.07)
Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:56AM CST
PFE: 30.25 (-0.17), MRK: 58.97 (-0.57), BMY: 57.68 (-0.12), NVS: 93.87 (-0.51)
Merck Joins Kenya Ministry Of Health Kenya Diabetes Management and Information Center (DMI) to Celebrate The World Diabetes Day
M2 - Thu Nov 13, 9:11AM CST
o Merck supports diabetes medical education and community awareness as part of its Capacity Advancement Program - CAP in Kenya.
MRK: 58.97 (-0.57)
Merck Aims to Support Free Diabetes Screening For More Than 15,000 Community Members in collaboration with Maharashtra University as Part of Its Capacity Advancement Program In India
M2 - Thu Nov 13, 9:11AM CST
o On the occasion of World Diabetes Day, Merck is conducting Diabetes awareness camps at 15 medical colleges in Maharashtra University.
MRK: 58.97 (-0.57)
BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - Thu Nov 13, 8:10AM CST
PFE: 30.25 (-0.17), MRK: 58.97 (-0.57), AZN: 72.73 (-1.80), BIND: 10.21 (+0.30)
Gene mutation targeted by Merck's Zetia leads to lower cholesterol levels and reduced heart disease risk
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:01AM CST
MRK: 58.97 (-0.57)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 58.97 (-0.57), INCY: 68.72 (-2.49), CLDX: 13.73 (-0.53), NLNK: 30.59 (-0.41), GSK: 45.70 (+0.04), BMY: 57.68 (-0.12), SRNE: 4.13 (-0.08)
Samsung Leads in Printed, Flexible and Organic Electronics Innovation
Marketwired - Thu Nov 13, 6:30AM CST
Samsung, Merck, BASF, Sony and Philips are the world's leading innovators in printed, flexible and organic electronics (PFOE), according to Lux Research, which rated corporations based on both internal R&D spending and open innovation activities. Samsung Electronics is the standout with estimated PFOE R&D spending of $1.2 billion, as well as high open innovation scores due to its extensive outside partnerships and investments.
MRK: 58.97 (-0.57)
Acute Coronary Syndrome: Global Drug Forecast and Market Analysis to 2023 - Market to Triple from $12.3 Billion in 2013 to $43.4 Billion by 2023
M2 - Thu Nov 13, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/mhkp4w/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023" report to their offering. New Blockbuster Drugs to More than Triple Acute Coronary Syndrome Treatment Market Value by 2023 The launch of several drugs with extraordinary blockbuster potential will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023 This report states that across seven major markets (the US, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (mAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape. Amgen's evolocumab, Sanofi and Regeneron's alirocumab, and Pfizer's bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and The authors expects these treatments to be launched in the middle of the forecast period. Eric J. Dimise, Ph.D., The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: These three mAbs, which fulfill a critical unmet need by offering novel approaches to LDL-C reduction for patients who cannot tolerate statins, are likely to be prescribed long-term, marking the first time that biologics will enter the mainstream of chronic ACS treatment. The premium price of PCSK9 mAbs means that they will be able to achieve substantial sales with a relatively small patient population. We forecast that they will account for around 40% of ACS sales by 2023, with a global value that slightly exceeds $17.5 billion. The authors has also identified two new anticoagulants, Janssen's Xarelto and Merck's Zontivity, which are both on track to compete directly with warfarin and post impressive sales over the next nine years. Dimise states: Xarelto is anticipated to achieve approval for the ACS indication in the US by 2018. When added to the drug's mounting sales in the EU, this will result in peak-year sales approaching $8 billion for ACS alone. Meanwhile, the PAR1 inhibitor, Zontivity, which enters the US market in Q3 of 2014, could achieve worldwide sales exceeding $1 billion by 2015. The dramatic increase in overall ACS market value is attributable to the launch of these and several other drugs currently in the late-stage development pipeline, all of which have extraordinary blockbuster potential, concludes the analyst. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AstraZeneca - Bristol-Myers Squibb - Daiichi Sankyo - Eli Lilly - GlaxoSmithKline - Janssen Pharmaceuticals (Johnson & Johnson) - The Medicines Company - Merck & Co. - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/mh...harmapoint
JNJ: 108.18 (-0.89), MRK: 58.97 (-0.57), AMGN: 156.93 (-3.92), LLY: 67.16 (-0.52), GSK: 45.70 (+0.04), BMY: 57.68 (-0.12)
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.69 (+0.20), MRK: 58.97 (-0.57), ABBV: 63.70 (+0.07)
Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
Shock Exchange - at Seeking Alpha - Wed Nov 12, 2:13PM CST
GILD: 101.53 (-2.67), MRK: 58.97 (-0.57)
Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - Wed Nov 12, 12:44PM CST
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote. The reason, he said, is...
JNJ: 108.18 (-0.89), PFE: 30.25 (-0.17), MRK: 58.97 (-0.57), AMGN: 156.95 (-3.90), MO: 48.65 (-0.80), CVX: 115.92 (-0.53)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.00 (-0.24), AGN: 197.90 (+1.69), HLF: 38.29 (+0.44), VRX: 134.35 (+2.45), PFE: 30.25 (-0.17), MRK: 58.97 (-0.57), LLY: 67.16 (-0.52)
This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 101.53 (-2.67), ACHN: 13.69 (+0.20), MRK: 58.97 (-0.57)
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 58.97 (-0.57), NVS: 93.87 (-0.51)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.52 (+0.01), JNJ: 108.18 (-0.89), IDRA: 2.40 (-0.05), DERM: 15.83 (-0.41), MRK: 58.97 (-0.57), PFE: 30.25 (-0.17), AZN: 72.73 (-1.80), AMGN: 156.95 (-3.90), GSK: 45.70 (+0.04), HSP: 57.98 (-0.11), NVS: 93.87 (-0.51), CELG: 103.04 (-4.39)
Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 101.52 (-2.68), MRK: 58.97 (-0.57)
